Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas - Jansen, Philipp; Galetzka, Wolfgang; Lodde, Georg C.; Standl, Fabian; Zaremba, Anne; Herbst, Rudolf; Terheyden, Patrick; Utikal, Jochen; Pföhler, Claudia; Ulrich, Jens; Kreuter, Alexander; Mohr, Peter; et al. (European journal of cancer, 2024)
Online verfügbar: 6. Juli 2024, Artikelversion: 16. Juli 2024